This project aims to evaluate the safety and usefulness of single nucleotide polymorphism (SNP)-based genetic tests for individual prostate cancer risk prediction by prospective testing in a clinical setting Furthermore, a follow-up control programme for high-risk individuals and an evaluation of the safety, compliance, and effect of excluding low-risk individuals from repeated PSA testing is establish.


Michael Borre MD, professor, PhD, DMSci.